

FORM 51-102F3
MATERIAL CHANGE REPORT

1. Name and Address of Company

NuGen Medical Devices Inc. (formerly BuzBuz Capital Corp.) (the “**Company**”)
1 Yonge Street, Suite 1801
Toronto, ON M5E 1W7

2. Date of Material Change

October 19, 2021

3. News Release

A press release disclosing the material change was released on October 19, 2021, through the facilities of Newsfile Corp.

4. Summary of Material Change

NuGen Medical Devices Inc. (formerly BuzBuz Capital Corp.) closed its previously announced business combination (the “**Transaction**”) with Inolife R&D Inc. (“**Inolife**”). The Transaction consisted of the acquisition by the Company of all of the issued and outstanding common shares in the capital of Inolife by way of a three-cornered amalgamation, pursuant to which a wholly-owned subsidiary of the Company amalgamated with Inolife and each Inolife shareholder received one (1) post-consolidation common share in the capital of the Company for each post-consolidated Inolife common share held, following the consolidation of the Inolife common shares on a three (3) for one (1) basis. As part of the Transaction, the Company changed its name from “BuzBuz Capital Corp.” to “NuGen Medical Devices Inc.” and the directors and management of Inolife became the directors and management of the Company.

5. Full Description of Material Change

Following the completion of the Transaction, Inolife (now renamed EPG Global Ltd.) is now a wholly-owned subsidiary of the Company, and the Company meets the listing requirements for a “Tier 2” life sciences issuer on the TSX Venture Exchange (the “**Exchange**”). The Company will continue the business of Inolife, which is an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies. Inolife has commercialized needle-free injection systems for the administration of subcutaneous medication, which is approved for sale in over 40 countries globally. Trading in the common shares of the Company is expected to begin on the Exchange in late October under the symbol “NGMD”.

Prior to the Transaction, the Company was a Capital Pool Company (as defined under the policies of the Exchange), and had not commenced commercial operations and had no assets other than cash. In connection with the Transaction, on October 15, 2021, the Company consolidated its common shares on the basis of one (1) post-consolidation common share for each two (2) pre-consolidation common shares. The Transaction constituted the Company’s “Qualifying Transaction”, as such term is defined in Policy 2.4 of the Exchange.

In connection with the Transaction, Inolife completed a brokered private placement through Canaccord Genuity Corp. of 15,000,000 subscription receipts at a price of \$0.40 per subscription receipt for gross proceeds of \$6 million. Each subscription receipt was deemed automatically converted into one unit (a “Unit”) of Inolife, without the payment of additional consideration or the taking of further action on the part of the subscriber. Each Unit is comprised of one common share in the capital of Inolife and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to acquire one common share in the capital of Inolife (each, a “Warrant Share”) at a price of C\$0.70 per Warrant Share for a period of twelve months following the satisfaction of the Escrow Release Conditions. All Units under the financing were exchanged for equivalent securities of the Company in connection with the terms of the Transaction.

As part of the Transaction, common share purchase warrants, stock options, convertible debentures of Inolife were replaced with similar securities of the Company with adjustments to their exercise or conversion terms to reflect the exchange ratio for the Inolife common shares under the Transaction.

Following the completion of the Transaction, the Company currently has a total of 86,014,961 common shares outstanding, as well as: (i) common share purchase warrants exercisable to purchase up to 14,705,602 common shares at exercise prices ranging from \$0.30 to \$0.90; (ii) stock options exercisable to purchase 700,000 common shares at exercise prices ranging from \$0.20 to \$0.90; and (iii) EUR6,235,000 principal amount of convertible debentures convertible into common shares of the Company at a price of CAD \$2.85 per common share.

An aggregate of 29,576,340 common shares are subject to escrow pursuant to Exchange escrow requirements.

As a result of the closing of the Transaction, the directors and executive officers of the Company are now:

Michael Wright	President, Chief Executive Officer and Director
Veronique Laberge	Chief Financial Officer
Nicky Canton	Chief Operating Officer
Derek Lindsay	Director
Karen Dunlap	Director
John Leombruno	Director
William Cleman	Director
Michael Wekerle	Director

6. Reliance on subsection 7.1(2) of National Instrument 51-102

The report is not being filed on a confidential basis.

7. Omitted Information

No significant facts have been omitted from this Material Change Report.

8. Executive Officer

For further information, please contact Michael Wright, President and Chief Executive Officer of the Company at (514) 992-9484.

9. Date of Report

This report is dated at Toronto, this 20th day of October, 2021.